Pang Jing-yao, Zhao Kui-jun, Wang Jia-bo, Ma Zhi-jie, Xiao Xiao-he
Clinical Pharmacy Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; China Military Institute of Chinese Medicine, 302 Military Hospital, Beijing 100039, China; Integrative Medicine Center, 302 Military Hospital, Beijing 100039, China.
J Zhejiang Univ Sci B. 2014 Jun;15(6):533-9. doi: 10.1631/jzus.B1300307.
Although several antiviral drugs and vaccines are available for use against hepatitis B virus (HBV), hepatitis caused by HBV remains a major public health problem worldwide, which has not yet been resolved, and new anti-HBV drugs are in great demand. The present study was performed to investigate the anti-HBV activity of epigallocatechin-3-gallate (EGCG), a natural-origin compound, in HepG2 2.2.15 cells. The antiviral activity of EGCG was examined by detecting the levels of HBsAg and HBeAg in the supernatant and extracellular HBV DNA. EGCG effectively suppressed the secretion of HBsAg and HBeAg from HepG2 2.2.15 cells in a dose- and time-dependent manner, and it showed stronger effects at the level of 0.11-0.44 μmol/ml (50-200 μg/ml) than lamivudine (3TC) at 0.87 μmol/ml (200 μg/ml). EGCG also suppressed the amount of extracellular HBV DNA. The data indicated that EGCG possessed anti-HBV activity and suggested the potential of EGCG as an effective anti-HBV agent with low toxicity.
尽管有几种抗病毒药物和疫苗可用于对抗乙型肝炎病毒（HBV），但由HBV引起的肝炎仍然是全球主要的公共卫生问题，尚未得到解决，因此对新型抗HBV药物的需求很大。本研究旨在调查天然来源的化合物表没食子儿茶素-3-没食子酸酯（EGCG）在HepG2 2.2.15细胞中的抗HBV活性。通过检测上清液中HBsAg和HBeAg的水平以及细胞外HBV DNA来检查EGCG的抗病毒活性。EGCG以剂量和时间依赖性方式有效抑制HepG2 2.2.15细胞中HBsAg和HBeAg的分泌，并且在0.11 - 0.44μmol/ml（50 - 200μg/ml）水平时比0.87μmol/ml（200μg/ml）的拉米夫定（3TC）表现出更强的作用。EGCG还抑制细胞外HBV DNA的量。数据表明EGCG具有抗HBV活性，并提示EGCG作为一种低毒性的有效抗HBV药物的潜力。
